A New Positron Emission Tomography Probe for Orexin Receptors Neuroimaging

Ping Bai 1,2,3, Sha Bai 2, Michael S. Placzek 2, Xiaoxia Lu 1, Stephanie A. Fiedler 2, Brenda Ntaganda 2, Hsiao-Ying Wey 2 and Changning Wang 2,*

1 Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China; pbai@mgh.harvard.edu (P.B.); luxx@cib.ac.cn (X.L.)
2 Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA; sbai@mgh.harvard.edu (S.B.); michael.placzek@mgh.harvard.edu (M.S.P.); sfiedler@mgh.harvard.edu (S.A.F.); bntaganda@mgh.harvard.edu (B.N.); hsiaoying.wey@mgh.harvard.edu (H.-Y.W.)
3 University of Chinese Academy of Sciences, Beijing 100049, China
* Correspondence: cwang15@mgh.harvard.edu

Received: 17 December 2019; Accepted: 20 February 2020; Published: 25 February 2020

Abstract: The orexin receptor (OX) is critically involved in motivation and sleep-wake regulation and holds promising therapeutic potential in various mood disorders. To further investigate the role of orexin receptors (OXRs) in the living human brain and to evaluate the treatment potential of orexin-targeting therapeutics, we herein report a novel PET probe ([11C]CW24) for OXRs in the brain. CW24 has moderate binding affinity for OXRs (IC50 = 0.253 μM and 1.406 μM for OX1R and OX2R, respectively) and shows good selectivity to OXRs over 40 other central nervous system (CNS) targets. [11C]CW24 has high brain uptake in rodents and nonhuman primates, suitable metabolic stability, and appropriate distribution and pharmacokinetics for brain positron emission tomography (PET) imaging. [11C]CW24 warrants further evaluation as a PET imaging probe of OXRs in the brain.

Keywords: orexin receptors; PET; radiotracer; imaging

1. Introduction

Orexin (OX) is a hypothalamic hypocretin peptide that mediates multiple functions such as arousal, attention, neuroendocrine, water balance, and pain modulation [1–6]. The orexin system has two peptide members, orexin-A and orexin-B with 33 amino acids and 28 amino acids, respectively [7]. Orexin receptors (OXRs) also have two subtypes (OX1R and OX2R). Orexin-A has similar binding affinities to OX1R and OX2R, while orexin-B has a 10-fold higher affinity for OX2R compared with OX1R. OXRs are differently expressed throughout the brain. OX1R is mainly expressed in the prefrontal and infralimbic cortex, hippocampus, paraventricular thalamic nucleus, and locus coeruleus [8]. OX2R is mainly distributed in the cerebral cortex, septal nuclei, lateral hypothalamus, hippocampus, and hypothalamic nuclei [9]. The differential distribution of OXRs in the brain may be responsible for the various physiological and psychiatric functions mediated by the OXR system [10–12].

Therapeutics targeting the orexin system have been investigated for various brain disorders such as insomnia [1,3], cluster headache [13], substance abuse [4,14], and maladaptation to stress [15,16]. This has led to the design and evaluation of orexin antagonists, including dual-OX1R and OX2R antagonists (DORA) and selective OX1R and OX2R antagonists (SORA) [7]. Almorexant [5] (ACT-426606) [17] from Actelion, SB-649868 [18] from GSK, and Suvorexant [6] from Merck are a few examples demonstrating the efforts from pharmaceutical companies. Among these compounds,
many have entered into clinical trials, however, Suvorexant is the only U.S. Food and Drug Administration (FDA) approved orexin drug for the insomnia market. The discovery of ORX antagonists provided powerful tool compounds to investigate the roles of the orexin system in a variety of biological processes. However, the roles of the orexin system in the brain are not well understood and further investigations with translational methods, such as in vivo imaging, are warranted.

A non-invasive molecular imaging with positron emission tomography (PET) is a unique tool to study the living brain, which provides a distinct advantage to quantify receptor expression and/or drug occupancy of novel ligands in vivo. Over the last decade, though there have been major advances in the development of orexin antagonists [19–25], no PET radiotracer is available for OXR imaging in the human brain. This limits our ability to investigate the orexin system in the human brain and hinders the potential of orexin-targeting neurotherapeutics for brain disorders.

To bridge the gap, several orexin antagonists have been radiolabeled by our group, as well as others. Most of the early discovery attempts resulted in compounds with low brain uptake or strong P-glycoprotein (P-gp) binding, including [11C]MK-1064 [26], [11C]EMPA [27], [11C]BBAC [28], and [11C]CW4 [29] (Figure 1). Towards the development of a successful OXR brain-PET imaging probe, we report the discovery and evaluation of [11C]CW24 with good brain uptake, suitable metabolic stability, and pharmacokinetics based on animal imaging studies in rodents and non-human primates.

![Figure 1. structures of orexin receptor radioligands.](image)

2. Results and Discussion

2.1. Selection of Scaffold for Orexin Imaging Probe Development.

Several small molecules have been reported as DORA or SORA [20,30,31]. Previously, our group has radiolabeled several DORAs based on a 1,4-diazepane scaffold [27,29]. However, the low brain uptake limited their further evaluation as a brain-PET radiotracer. Recently, IPSU was reported as an OX2R selective antagonist with good brain uptake [32,33]. It has been studied in rodents, including blood and brain pharmacokinetics, as well as EEG (electrocorticogram/electroencephalogram) and EMG (electromyogram) recordings following treatment with these OXR antagonists in mice. Based on the structure-activity relationship (SAR) study of ISPU analogs, methylation of the indole imine does not disrupt OXR antagonism [32]. Hence, we chose the indole imine of IPSU as the radiolabeling site and synthesized CW24. The affinity of CW24 for orexin receptors (OX1R and OX2R) in cells was measured in a competition binding assay against [125I]orexin. CW24 displayed potent activity at OXR (IC50 0.253 μM OX1R, 1.406 μM OX2R). Compared to IPSU binding, this was ~5 fold (OX1R) and ~2 fold (OX2R) increase in potency, warranting further evaluation.
2.2. Physicochemical Properties of CW24

Lipophilicity (logP) and molecular weight need to be optimized for sufficient blood-brain barrier (BBB) penetration while also avoiding high non-specific binding. Studies have shown that it is preferred for clogP ≤ 4, clogD ≤ 3, total polar surface area (tPSA) between 30–75 and molecular weight (M.W.) < 500 for successful brain-PET imaging probes[34,35]. IPSU is reported as a non-selective OXR antagonist with good brain uptake[33]. CW24, the methylated form of IPSU, had favorable properties for CNS penetration (M.W. = 419.5, Log D(7.4) = 2.3, tPSA = 60.74, IC_{50} = 0.253 μM and 1.406 μM for OX1R and OX2R, respectively) (Figure 2). Furthermore, we tested the off-target binding of CW24 in vitro, [36] and were pleased to see that CW24 was selective for OXRs compared to 40 other CNS targets(National Institute of Mental Health Psychoactive Drug Screening Program, NIMH PDSP) (Table S1).

|       | Mw.   | Log D | tPSA  | IC_{50} (nM) | OXR1 | OXR2 |
|-------|-------|-------|-------|--------------|------|------|
| IPSU  | 405.5 | n.t.  | 69.53 | 1090         | 3135 |
| CW24  | 419.5 | 2.3   | 60.74 | 253          | 1406 |
| Suvorexant | 450.93 | n.t.  | 73.1  | 27           | 16   |

Figure 2. Structures and physicochemical properties of IPSU and CW24 (n.t. = not tested). IC_{50} of IPSU, CW24 and suvorexant were measured by a radioligand competition binding assay.

2.3. Chemical Synthesis for CW24 and [^{11}C]CW24

CW24 was prepared from IPSU via direct methylation in the presence of a base (Figure S1 and S2). [^{11}C]CW24 was radiosynthesized from IPSU (0.5 mg) in DMF (1 mL) with KOH (10 mg) and allowed to react with [^{11}C]CH3I for 3 min at 100 °C (Scheme 1). The average synthesis time was 30–35 minutes from end of cyclotron bombardment (EOB) to end of synthesis (EOS), the radiochemical yield (RCY) was 10–21% (non-decay corrected from trapped [^{11}C]CH3I), the specific activity (A) was 1.28 ± 0.2 mCi/nmol (EOS), the chemical and radiochemical purities of [^{11}C]CW24 were ≥ 97%.

Scheme 1. Radiolabeling condition: IPSU (precursor, 0.5 mg), [^{11}C]CH3I, KOH (10 mg), in 1.0 mL DMF, 3 min, 100 °C. Radiochemical yield (RCY): 10–21% (non-decay corrected from trapped [^{11}C]CH3I).

2.4. Mouse Imaging with [^{11}C]CW24

We performed PET-computed tomography (CT) imaging on mice to test [^{11}C]CW24 as a neuroimaging probe for OXR imaging in vivo. [^{11}C]CW24 exhibited high brain uptake (%ID/cc = 3.5% at C_{max}, 1.5 min post-injection). In general, %ID/cc above 0.1% in rat or 0.01% in non-human primate
within 5 min post-injection is above the threshold for suitable BBB penetration for CNS PET imaging studies [37]. Next, to evaluate the specificity of $^{[11]}$C]CW24 for OXRs, PET-CT imaging studies were performed in mice after 5 min pretreatment with IPSU (0.5 and 2.0 mg/kg; i.v.) or Suvorexant (5.0 mg/kg; i.v.). Time-activity curves (TACs) were normalized for peak uptake (~20 seconds post-injection in these studies) (Figure 3). Approximately 10% reduction in $^{[11]}$C]CW24 uptake with 0.5 mg/kg IPSU administration in 30–60 mins post-injection of $^{[11]}$C]CW24. In addition, approximately 50% reduction was found when the blocking dose of IPSU was increased to 2.0 mg/kg. Suvorexant (5.0 mg/kg) administration at 30–60 mins post-injection of $^{[11]}$C]CW24 also showed ~50% reduction in the mouse brain. Following IPSU pretreatment, $^{[11]}$C]CW24 binding was reduced in a dose-dependent manner in the brain for the relative radioactivity changes after administration. These results strongly support that $^{[11]}$C]CW24 binds selectively to the OXRs in vivo.

Figure 3. (A) The PET/CT imaging of $^{[11]}$C]CW24 focused on mice brain (20–60 min after intravenous administration (i.v.)); (B) baseline and blocking time-activity curve (TAC) of $^{[11]}$C]CW24 and (C) TAC after normalized the brain uptake curves with the highest uptake time point (20 seconds post-injection).

2.5. Non-human Primate (NHP) Imaging with $^{[11]}$C]CW24

Encouraged by the promising imaging results of $^{[11]}$C]CW24 in mice, we performed PET-Magnetic resonance imaging (MR) imaging in a NHP (Figures 4&5). In macaque, $^{[11]}$C]CW24 demonstrated high brain uptake. We observed a peak standard uptake value (SUV) (SUV=C(T)/(injected dose/body weight) between 1.5–3.0 for all brain regions examined (Figure 4A). Furthermore, relatively higher uptake was observed in the midbrain and the thalamus and lower uptake in the hippocampus which suggests heterogenous expressions of OXR in the macaque brain. To further investigate the specific binding of $^{[11]}$C]CW24, a blocking study was performed in which 2.0 mg/kg IPSU was administered 5 min prior the PET-MR acquisition. Similar to the blocking results shown in mice, a reduction of radioactivity uptake was found in several brain regions including hippocampus, nucleus accumbens, thalamus, hypothalamus, putamen and cerebellum (Figure 4B). Using the arterial blood data as input function, Logan graphical analysis was applied to quantify volume of distribution (Vr, mL/cm$^3$) of $^{[11]}$C]CW24 (Figure 5). The metabolite-corrected arterial plasma after $^{[11]}$C]CW24 bolus injection is showed in Figure 5C.
Figure 4. (A) Positron emission tomography (PET)-Magnetic resonance (MR) Imaging (macaque brain). Summed PET images (30–90 min after $[^{11}]$CW24 injection) superimposed structural MRI from the same macaque. (B) Time–activity curves for brain regions of interest from baseline and blocking scans are shown (2.0 mg/kg IPSU) (a) hippocampus, (b) nucleus accumbens, (c) thalamus, (d) hypothalamus, (e) putamen and (f) cerebellum.

Figure 5. Kinetic modeling results with $[^{11}]$CW24 in the macaque brain. (A) The total volume of distribution ($V_T$) images derived from Logan plot with arterial blood data as input function (color bar indicates $V_T$ values from 1–2.5 mL/cm$^3$ (blue to red); (B) Regional $V_T$ values showed that the expression difference in brain regions; (C) Arterial plasma analysis showed that $[^{11}]$CW24 radioactivity was rapidly cleared from blood and $[^{11}]$CW24 stability evaluated in plasma over time showed lasting presence of ~47% of parent compound at 30 min.
Based on our evaluation both in rodents and NHPs in vivo, $[^{11}\text{C}]$CW24 is a promising OXR PET radioligand candidate. It has been reported that OXR was typically present in the cerebral cortex, septal nuclei, hippocampus, medial thalamic groups, raphe nuclei, and abundantly expressed in hypothalamic nuclei that regulate the homeostasis in rodents.[12] In addition, OX$_2$R was found to have expression in the hypothalamus that enables its unique role of sleep-wake regulation.[11] Compare to the previous OXR probes we developed[27,29] $[^{11}\text{C}]$CW24 had higher brain uptake, increased isoform selectivity over IPSU, appropriate kinetics and distribution, which warrants further development of OXR PET radioligands based on $[^{11}\text{C}]$CW24.

3. Materials and Methods

3.1. Synthesis of Compound CW24

A mixture of IPSU (5 mg, 0.012 mmol, purchased from MedChemExpress), KOH (4 mg, 0.06 mmol), and CH$_3$I (5 mg, 0.036 mmol) in DMF (0.1 mL) were reacted at room temperature overnight. The reaction mixture was purified by reverse phase chromatography (H$_2$O: CH$_3$CN = 1:1) to give the desired product (2 mg, 0.005 mmol, 39% yield) as a white solid. $^1$H-NMR (500 MHz, Chloroform-d) δ 8.04 (d, $J$ = 5.6 Hz, 1H), 7.64 (d, $J$ = 7.9 Hz, 1H), 7.29 (d, $J$ = 8.2 Hz, 1H), 7.22 (t, $J$ = 7.7 Hz, 1H), 7.10 (t, $J$ = 7.4 Hz, 1H), 7.02 (s, 1H), 5.93 (s, 1H), 4.72 (s, 2H), 4.40 (dt, $J$ = 13.7, 4.7 Hz, 2H), 3.87 (s, 3H), 3.75 (s, 3H), 3.38 (m, 2H), 3.24 (t, $J$ = 6.1 Hz, 2H), 2.24 (m, 2H), 1.83–1.77 (m, 2H), 1.73 (m, 2H), 1.50 (m, 2H).$^{13}$C-NMR (125 MHz, Chloroform-d) δ 174.50, 169.94, 161.78, 157.98, 137.12, 128.79, 127.61, 121.89, 119.68, 119.41, 110.84, 109.29, 95.96, 53.00, 46.79, 41.77, 40.27, 39.80(2), 33.84(2), 32.82, 30.61, 18.91. LC-MS [M]+ 419.85.

3.2. Radiosynthesis of $[^{11}\text{C}]$CW24

$[^{11}\text{C}]$CH$_3$I was trapped in a reactor (TRACERlab FX-M synthesizer, General Electric) preloaded with the precursor (0.5 mg), KOH (5.0 mg) in 1.0 mL dry DMF. The mixture was stirred for 3 min at 100 °C and followed by adding water (1.2 mL). The product was separated by reverse phase semi-preparative HPLC (Phenomenex Luna 5u C8(2), 250 mm × 10 mm, 5 μm; 5.0 mL/min; 60% H$_2$O + ammonium formate (0.1 M)/ 40% CH$_3$CN; isocratic). The collected final product was loaded onto a C-18 sep-pak cartridge, and rinsed with water (5 mL), eluted with EtOH (0.3 mL), and saline (0.9%, 2.7 mL). The average time required for the synthesis from EOB to EOS was 30–35 min. The average radiochemical yield (RCY) was 10%–21% (non-decay corrected to trapped $[^{11}\text{C}]$CH$_3$I). Chemical and radiochemical purities were ≥ 95 % (measured with HPLC equipped with a UV detector and a gamma detector) with a specific activity ($A_s$) of 1.28 ± 0.2 mCi/nmol (EOS).

3.3. Assessment of Lipophilicity (Log D; pH 7.4))

LogD was determined according to methods identical to those we previously reported[38].

3.4. Human Orexin GPCR Binding (Agonist Radioligand) Assay

Radioligand competition binding assays were performed by Panlabs, Eurofins Pharma Discovery Services. Briefly, human recombinant orexin OX1 receptors expressed in CHO-S cells were used in modified HEPES buffer pH 7.4. An aliquot was incubated with 0.1 nM $[^{125}\text{I}]$Orexin A for 60 minutes at 25 °C. Receptors were filtered and then counted to determine $[^{125}\text{I}]$Orexin A specifically binding. Human recombinant OX2 receptors were used in modified HEPES buffer pH 7.4. An aliquot was incubated with 0.04 nM $[^{125}\text{I}]$Orexin A for 180 minutes at 25 °C. Membranes were filtered and then counted to determine $[^{125}\text{I}]$Orexin A specifically bound.

3.5. Rodent PET/CT Acquisition

The Subcommittee on Research Animal Care (SRAC) serves as the Institutional Animal Care and Use Committee (IACUC) for the Massachusetts General Hospital (MGH). SRAC reviewed and approved all procedures detailed in this paper. B6C3F1/J mice (male, 18-month old; $n$ = 4 total) were
utilized in this study. IPSU and Suvorexant were purchased from MedChemExpress and dissolved in 1.0% DMSO + 1.0% Tween 80 + 98.0% saline to make a solution of 1.0 mg/mL.

Animals were anesthetized with 1–1.5% isoflurane and maintained with isoflurane during the imaging scan. In a single imaging session, mice were arranged in a Triumph PET/CT scanner (Gamma Medica, Northridge, CA). The mice were administered $^{11}$C CW24 (3700–7400 KBq per animal) after 5-min pre-treatment of IPSU (0.5 and 2.0 mg/kg; $n=1$ for each dose; i.v.), Suvorexant (5.0 mg/kg; $n=1$; i.v.), or vehicle ($n=1$) via a lateral tail vein catheter. Animals underwent a 60 min dynamic PET scan followed by computed tomography (CT).

3.6. Rodent PET/CT Image Analysis

PET data were reconstructed using a 3D-MLEM method resulting in a full width at half-maximum resolution of 1 mm. PET and CT images in DICOM format were imported to PMOD (PMOD Technologies, Ltd. Zürich, Switzerland) and co-registered to the brain atlas. Volumes of interest (VOIs) were drawn as spheres in brain regions guided by CT structural images and summed PET data. Time-activity curves (TACs) were exported as activity per unit volume (%ID/cc) for analysis.

3.7. Macaque PET-MR Acquisition

A male rhesus macaque (14.4 kg) was included in this study. After endotracheal intubation, the macaque was catheterized antecubital for radiotracer injection and a radial arterial line was placed for arterial blood sampling and radiometabolite analysis. The animal was anesthetized with 1.2–1.3% isoflurane in medical oxygen throughout the imaging session. PET-MR data was acquired on a 3T Siemens MRI scanner (Munich, Germany) with a BrainPET insert. A baseline and a blocking scan were performed on the same animal. Dynamic PET image acquisition was initiated followed by a bolus administration of $^{11}$C CW24 (179 MBq for the baseline scan and 192 MBq for the blocking scan). To characterize the specific binding of $^{11}$C CW24, a blocking study was carried out in which 2.0 mg/kg IPSU (1.0% DMSO + 1.0% Tween 80 + 98.0% saline to make a solution of 1.0 mg/mL) was administered 5 min prior the acquisition. A T1-weighting multi-echo magnetization-prepared rapid gradient-echo (MEMPRAGE) sequence began as the PET scan for anatomic co-registration. Dynamic PET data were corrected for decay, scatter, and attenuation and reconstructed using methods similar to our previous studies[39].

3.8. PET-MR Imaging Data Analysis for the Macaque Study

Motion-corrected PET data were registered to the INIA19 macaque MRI Template. VOIs were selected according to the INIA19 Template and NeuroMaps Atlas[40]. TACs from the whole Macaque brain as well as a few brain regions were exported. With the availability of a metabolite-corrected arterial plasma data, the regional volume of distribution ($V_r$) was calculated using Logan Plot analysis (with a fixed t* of 40 min).

3.9. Plasma and Metabolite Analysis.

Briefly, arterial blood samples collected (every 10 s at first 3 min post-administration of $^{11}$C CW24, then 5 min, 10 min, 20 min, 30 min, 45 min, 60 min, and 90 min) during macaque imaging were centrifuged to separate plasma, which was then removed and placed in an automated gamma counter [41]. Metabolite analysis of blood samples collected from 5 to 90 min was conducted on a custom automated robot fitted with Phenomenex SPE Strata-X 500 mg solid phase extraction cartridges that were primed with ethanol (2 mL) and deionized water (20 mL). Protein precipitation was achieved by the addition of plasma (300 µL) to acetonitrile (300 µL), which was centrifuged for 1 min to obtain protein-free plasma (PFP). Three hundred microliters of PFP/acetonitrile solution was diluted into deionized water (3 mL), loaded onto the C18 cartridge, and removed of polar metabolites with 100% water. Next, a series of extractions was performed using water and acetonitrile. Each
sample was counted in a WIZARD2 Automatic Gamma Counter to determine the presence of radiolabeled metabolites.

4. Conclusions

In summary, our developed PET imaging radio-ligands, $[^{11}\text{C}]CW24$, provides a non-invasive quantitative imaging tool for evaluating OXR expression in the brain. Based on the in vitro and in vivo evaluations, $[^{11}\text{C}]CW24$ had high brain uptake and good target-selectivity, but suffers from high non-specific binding. Therefore, $[^{11}\text{C}]CW24$ could be used as a lead compound to develop brain-PET probes for OXRs to investigate not only the roles of OXR in a variety of disease applications, but also the development of OXR neurotherapeutics. In future studies, it is important that we characterize and optimize $[^{11}\text{C}]CW24$ to improve specific binding for developing potential PET imaging probes for human imaging.

Supplementary Materials: The following are available online, Figure S1: Representative $^1\text{H}$, $^{13}\text{C}$-NMR and HPLC data for CW24; Figure S2: The HPLC profile of CW24; Table S1: Off-target binding data of CW24.

Author Contributions: Investigation, P.B., S.B.; writing—original draft preparation, P. B.; writing—review and editing, M.P., B.N., S.A.F., H.-Y. W.; supervision, X.L.; project administration, C.W.; funding acquisition, C.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by National Institutes of Health (NIH), grant number DA048123 and the APC was funded by NIH-DA048123.

Acknowledgments: This work was supported by NIH funding (DA048123) and pilot funding from the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (C.W. and H.-Y. W.). The imaging studies were carried out at the Martinos Center, using resources provided by the Center for Functional Neuroimaging Technologies, P41EB015896, a P41 Regional Resource supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers: S10RR017208, S10RR026666, S10RR022976, S10RR019933, S10RR023401. The author Ping Bai gratefully acknowledges financial support by China Scholarship Council (CSC) for this training at the Martinos Center. The authors are grateful to (Judit Sore, the Martinos Center radioligand lab, PET/MR imaging staff (Grae Arabasz, Shirley Hsu and Regan Butterfield), and Helen Deng for assistance with non-human primate imaging.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ammoun, S.; Holmqvist, T.; Shariatmadari, R.; Oonk, H.B.; Detheux, M.; Parmentier, M.; Akerman, K.E.; Kukkonen, J.P. Distinct recognition of OX1 and OX2 receptors by orexin peptides. J. Pharmacol. Exp. Ther. 2003, 305, 507–514.

2. Bettica, P.; Squassante, L.; Groeger, J.A.; Gennery, B.; Winsky-Sommerer, R.; Dijk, D.J. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012, 37, 1224–1233.

3. Bingham, M.J.; Cai, J.; Deehan, M.R. Eating, sleeping and rewarding: orexin receptors and their antagonists. Curr. Opin Drug Discov. Devel. 2006, 9, 551–559.

4. Boutrel, B.; Kenny, P.J.; Specio, S.E.; Martin-Fardon, R.; Markou, A.; Koob, G.F.; de Lecea, L. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc. Natl. Acad. Sci. USA 2005, 102, 19168–19173.

5. Brisbare-Roch, C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S.L.; et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 2007, 13, 150–155.
6. Cada, D.J.; Levien, T.L.; Baker, D.E. Suvorexant. *Hosp Pharm.* 2015, 50, 59–71.
7. Roecker, A.J.; Cox, C.D.; Coleman, P.J. Orexin receptor antagonists: New therapeutic agents for the treatment of insomnia. *J. Med. Chem.* 2016, 59, 504–530.
8. Bingham, S.; Davey, P.T.; Babbs, A.J.; Irving, E.A.; Sammons, M.J.; Wyles, M.; Jeffrey, P.; Cutler, L.; Riba, I.; Johns, A.; et al. Orexin-A, an hypothalamic peptide with analgesic properties. *Pain* 2001, 92, 81–90.
9. Tabaeizadeh, M.; Motiei-Langroudi, R.; Mirbaha, H.; Esmaeili, B.; Tahsili-Fahadan, P.; Javadi-Paydar, M.; Ghaifarpour, M.; Dehpour, A.R., The differential effects of OX1R and OX2R selective antagonists on morphine conditioned place preference in naive versus morphine-dependent mice. *Behav. Brain Res.* 2013, 237, 41–48.
10. de Lecea, L.; Kilduff, T.S.; Peyron, C.; Gao, X.; Foye, P.E.; Danielsom, P.E.; Fukushima, C.; Battenberg, E.L.; Gautvik, V.T.; Frankel, W.N.; et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc. Natl. Acad. Sci. USA* 1998, 95, 322–327.
11. Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R.M.; Tanaka, H.; Williams, S.C.; Richardson, J.A.; Kozlowski, G.P.; Wilson, S.; et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 1998, 92, 573–585.
12. Marcus, J.N.; Aschkenasi, C.J.; Lee, C.E.; Chemelli, R.M.; Saper, C.B.; Yanagisawa, M.; Elmquist, J.K. Differential expression of orexin receptors 1 and 2 in the rat brain. *J. Comp. Neurol.* 2001, 435, 6–25.
13. Suzuki, H.; Takemoto, Y.; Yamamoto, T. Differential distribution of orexin-A-like and orexin receptor 1 (OX1R)-like immunoreactivities in the Xenopus pituitary. *Tissue Cell* 2007, 39, 423–430.
14. Mahler, S.V.; Smith, R.J.; Moorman, D.E.; Sartor, G.C.; Aston-Jones, G. Multiple roles for orexin/hypocretin in addiction. *Prog. Brain Res.* 2012, 198, 79–121.
15. Ida, T.; Nakahara, K.; Murakami, T.; Hanada, R.; Nakazato, M.; Murakami, N. Possible involvement of orexin in the stress reaction in rats. *Biochem. Biophys. Res. Commun.* 2000, 270, 318–323.
16. Furlong, T.M.; Vianna, D.M.; Liu, L.; Carrive, P. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. *Eur. J. Neurosci.* 2009, 30, 1603–1614.
17. Stachulski, A.V.; Baillie, T.A.; Park, B.K.; Obach, R.S.; Dalvie, D.K.; Williams, D.P.; Srivastava, A.; Regan, S.L.; Antoine, D.J.; Goldring, C.E.; et al. The generation, detection, and effects of reactive drug metabolites. *Med. Res. Rev.* 2013, 33, 985–1080.
18. Betica, P.; Squassante, L.; Zamuner, S.; Nucci, G.; Danker-Hopfe, H.; Ratti, E. The orexin antagonist SB-649686 promotes and maintains sleep in men with primary insomnia. *Sleep* 2012, 35, 1097–1104.
19. Hirose, M.; Egashira, S.; Goto, Y.; Hashihayata, T.; Ohtake, N.; Iwaasa, H.; Hata, M.; Fukami, T.; Kanatani, A.; Yamada, K. N-acetyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. *Bioorg. Med. Chem. Lett.* 2003, 13, 4497–4499.
20. Whitman, D.B.; Cox, C.D.; Breslin, M.J.; Brasheer, K.M.; Schreier, J.D.; Bogusky, M.J.; Bednar, R.A.; Lemaire, W.; Bruno, J.G.; Hartman, G.D.; et al. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. *Chem. Med. Chem.* 2009, 4, 1069–1074.
21. Malherbe, P.; Borroni, E.; Pinard, E.; Wettstein, J.G.; Knoflach, F. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. *Mol. Pharmacol.* 2009, 76, 618–631.
22. MeAtee, L.C.; Sutton, S.W.; Rudolph, D.A.; Li, X.; Aluisio, L.E.; Phuong, V.K.; Dvorak, C.A.; Lovenberg, T.W.; Carruthers, N.I.; Jones, T.K. Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. *Bioorg. Med. Chem. Lett.* 2004, 14, 4225–4229.
23. Porter, R.A.; Chan, W.N.; Coulton, S.; Johns, A.; Hadley, M.S.; Widdowson, K.; Jerman, J.C.; Brough, S.J.; Coldwell, M.; Smart, D.; et al. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. *Bioorg. Med. Chem. Lett.* 2001, 11, 1907–1910.

24. Smart, D.; Sabido-David, C.; Brough, S.J.; Jewitt, F.; Johns, A.; Porter, R.A.; Jerman, J.C. SB-334867-A: the first selective orexin-1 receptor antagonist. *Br. J. Pharmacol.* 2001, 132, 1179–1182.

25. Srinivasan, S.; Simms, J.A.; Nielsen, C.K.; Lieske, S.P.; Bito-Onon, J.J.; Yi, H.; Hopf, F.W.; Bonci, A.; Bartlett, S.E. The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. *PLoS ONE* 2012, 7, e44726.

26. Gao, M.; Wang, M.; Zheng, Q.H. Synthesis of [(11)C]MK-1064 as a new PET radioligand for imaging of orexin-2 receptor. *Bioorg. Med. Chem. Lett.* 2016, 26, 3694–3699.

27. Wang, C.; Moseley, C.K.; Carlin, S.M.; Wilson, C.M.; Neelamegam, R.; Hooker, J.M. Radiosynthesis and evaluation of [(11)C]EMPA as a potential PET tracer for orexin 2 receptors. *Bioorg. Med. Chem. Lett.* 2013, 23, 3389–3392.

28. Liu, F.; Majo, V.J.; Prabhakaran, J.; Castrillion, J.; Mann, J.J.; Martinez, D.; Kumar, J.S. Radiosynthesis of [(11)C]BBAC and [(11)C]BBPC as potential PET tracers for orexin 2 receptors. *Bioorg. Med. Chem. Lett.* 2012, 22, 2172–2174.

29. Wang, C.; Wilson, C.M.; Moseley, C.K.; Carlin, S.M.; Hsu, S.; Arabasz, G.; Schroeder, F.A.; Sander, C.Y.; Hooker, J.M. Evaluation of potential PET imaging probes for the orexin 2 receptors. *Nucl. Med. Biol.* 2013, 40, 1000–1005.

30. Cox, C.D.; McGaughey, G.B.; Bogusky, M.J.; Whitman, D.B.; Ball, R.G.; Winrow, C.J.; Renger, J.J.; Coleman, P.J. Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding. *Bioorg. Med. Chem. Lett.* 2009, 19, 2997–3001.

31. Steiner, M.A.; Gatfield, J.; Brisbare-Roch, C.; Dietrich, H.; Treiber, A.; Jenck, F.; Boss, C. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. *Chem. Med. Chem.* 2013, 8, 898–903.

32. Betschart, C.; Hintermann, S.; Behnke, D.; Cotesta, S.; Fendt, M.; Gee, C.E.; Jacobson, L.H.; Laue, G.; Ofner, S.; Chaudhari, V.; et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. *J. Med. Chem.* 2013, 56, 7590–7607.

33. Callander, G.E.; Olorunda, M.; Monna, D.; Schuepbach, E.; Langenegger, D.; Betschart, C.; Hintermann, S.; Behnke, D.; Cotesta, S.; Fendt, M.; et al. Kinetic properties of “dual” orexin receptor antagonists at OX1R and OX2R orexin receptors. *Front. Neurosci.* 2013, 7, 230.

34. Zhang, L.; Villalobos, A.; Beck, E.M.; Bocan, T.; Chappie, T.A.; Chen, L.; Grimwood, S.; Heck, S.D.; Helal, C.J.; Hou, X.; et al. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. *J. Med. Chem.* 2013, 56, 4568–4579.

35. Seo, Y.J.; Kang, Y.; Muench, L.; Reid, A.; Caesar, S.; Jean, L.; Wagner, F.; Holson, E.; Haggarty, S.J.; Weiss, P.; et al. Image-guided synthesis reveals potent blood-brain barrier permeable histone deacyethylase inhibitors. *ACS Chem. Neurosci.* 2014, 5, 588–596.

36. Besnard, J.; Ruda, G.F.; Setola, V.; Abecassis, K.; Rodriguiz, R.M.; Huang, X.P.; Norval, S.; Sassano, M.F.; Shin, A.I.; Webster, L.A.; et al. Automated design of ligands to polypharmacological profiles. *Nature* 2012, 492, 215–220.

37. Van de Bittner, G.C.; Ricq, E.L.; Hooker, J.M. A philosophy for CNS radiotracer design. *Acc. Chem. Res.* 2014, 47, 3127–3134.
38. Wang, C.; Placzek, M.S.; Van de Bittner, G.C.; Schroeder, F.A.; Hooker, J.M. A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography. *ACS Chem. Neurosci.* 2016, 7, 484–489.

39. Wang, C.; Schroeder, F.A.; Hooker, J.M. Development of new positron emission tomography radiotracer for BET imaging. *ACS Chem. Neurosci.* 2017, 8, 17–21.

40. Rohlfing, T.; Kroenke, C.D.; Sullivan, E.V.; Dubach, M.F.; Bowden, D.M.; Grant, K.A.; Pfefferbaum, A. The INIA19 template and neuromaps atlas for primate brain image parcellation and spatial normalization. *Front. Neuroinform* 2012, 6, 27.

41. Bai, P.; Wey, H.-Y.; Patnaik D.; Lu, X.; Rokka, J.; Stephanie, F.; Haggarty, S.J.; Wang, C. Positron emission tomography probes targeting bromodomain and extra-terminal (BET) domains to enable in vivo neuroepigenetic imaging. *Chem. Commun.* 2019, 55, 12932–12935.

**Sample Availability:** Samples of the compounds (IPSU and CW24) are available from the authors.